The Daily Toke

March 21, 2026

Legalization pushes are accelerating across multiple states this week, even as federal uncertainty and local political divisions threaten to derail momentum. Tennessee Democrats have filed the "Pot for Potholes Act," linking marijuana legalization directly to infrastructure spending—a strategic move that ties cannabis revenue to tangible public goods rather than treating it as a standalone policy debate. Meanwhile, Louisiana lawmakers introduced House Bill 373, which would establish a limited "adult-use cannabis pilot program" running through 2030, though the proposal has already drawn fire from Attorney General Liz Murrill, who called expanded marijuana use "bad policy." The pilot structure is deliberately narrow: only existing medical marijuana operators—currently dominated by Good Day Farm and Ilera Holistic Healthcare—would be allowed to sell recreational cannabis, with each limited to a single dual-use retail location. 💰 MONEY MOVES Governor Josh Shapiro of Pennsylvania is betting big on legalization, projecting $729 million in new revenue for the 2026-27 budget, though his previous legalization proposal failed to pass the divided legislature last year, leaving unresolved debates about whether a new "Cannabis Control Board" or the state Liquor Control Board should oversee the market.

Ohio and Virginia are charting opposite trajectories, illustrating the political fragmentation defining cannabis policy nationwide. 🚀 THIS IS COOL Virginia's Cannabis Control Authority recently announced simplified licensing processes and new social equity programs designed to support minority-owned cannabis businesses—a model focused on inclusion and streamlined business entry. In sharp contrast, Ohio's Senate Bill 56 introduced sweeping restrictions to the state's voter-approved cannabis framework, including bans on intoxicating hemp products and THC/CBD beverages that took effect this week. A Franklin County judge rejected an 11th-hour legal challenge to block the restrictions before they went live, meaning Ohio residents now face new criminal charges for transporting cannabis outside a car's trunk or consuming it in public—rules that directly contradict what 57% of Ohio voters approved in November 2023.

The regulatory whiplash reflects deeper political divisions. Louisiana entrepreneur Monica Olano, founder of Cali Sober Market and Distribution, characterized Louisiana's pilot program as "a scam," arguing that the two-year exclusivity clause protecting current license holders blocks out competition and does nothing to address pricing or market access for consumers. Her critique highlights a pattern emerging across states: legalization bills are passing, but the structures written into law often entrench existing corporate players rather than opening genuine recreational markets.

Federal uncertainty is adding another layer of chaos. Rep. James Comer (R-KY), chairman of the House Oversight and Government Reform Committee, is urging Congress to delay new federal restrictions on hemp-derived THC products, citing the $28.4 billion market for hemp and cannabis. That market includes thousands of small businesses and millions of consumers who've relied on hemp-derived products—THC drinks, edibles, and other intoxicating products—in states where cannabis remains illegal. Ohio's new restrictions effectively criminalized many of these products, which means veterans and chronic pain patients who've found relief in legal hemp products now face limited options. 🤔 THINK ABOUT IT Federal restrictions on zero-overdose hemp products are being debated while alcohol continues to kill approximately 95,000 Americans annually and prescription opioids kill 16,000+—yet alcohol is legal and opioids are prescribed. Why is the regulatory urgency focused on a plant that has never caused an overdose death in recorded history?

March 21, 2026

Ohio's hemp restrictions took effect at midnight March 20th after a Franklin County judge rejected a last-minute legal challenge, effectively shutting down the state's thriving market for intoxicating hemp products outside regulated cannabis dispensaries. Senate Bill 56, which became law after a referendum effort by Ohioans for Cannabis Choice fell short on signatures, introduces sweeping restrictions: intoxicating hemp products can now only be sold through approved marijuana dispensaries, THC drinks are banned outright, the maximum THC level in extracts drops from 90 percent to 70 percent, and products containing more than 0.4 milligrams of THC face strict retail limitations. The law also prohibits smoking in most public spaces, bans interstate hemp transport, restricts advertisements claiming health benefits, and requires marijuana to be transported in vehicle trunks or back rows.

💰 MONEY MOVES The economic fallout was immediate and severe. Ohio breweries rushed through final production runs of THC beverages, shipping inventory across state lines to Kentucky and Indiana as quickly as possible. Craft brewers like Seventh Son Brewing, facing years of decline in the traditional beer market, had viewed THC drinks as a potential lifeline—one executive told reporters the beverages represented the difference between breaking even and a genuinely profitable year. Now that revenue stream has evaporated. The Party Source in Bellevue, Kentucky, stocked up on Ohio-produced THC drinks while they could, with manager Mary Holland noting that "our best-selling products come from Ohio." Holland also highlighted a regulatory irony: Kentucky structured its THC beverage market similarly to spirits and wine, with licensed distribution companies handling the products—a model she suggested would have been more surgical than Ohio's outright ban.

Meanwhile, Texas is about to deliver a similar blow to its smokable hemp market. New rules from the Texas Department of State Health Services taking effect March 31st will change how THC levels are calculated by factoring in THCA—the non-psychoactive precursor that converts to delta-9 THC when heated. 💰 MONEY MOVES That calculation shift will effectively eliminate smokable hemp products from retail shelves, devastating businesses where these products represent 50 to 70 percent of sales. Jacob Warner at Alamo Bud Co. expects all smokable inventory to be removed by end of business March 30th. The new Texas rules also raise annual licensing fees by more than 3,000 percent—retailers jumping from $155 to $5,000 annually, manufacturers from $258 to $10,000—a shock that business owners say will force closures across San Antonio and beyond. Governor Greg Abbott vetoed a complete THC ban in the previous legislative session but then ordered DSHS to revise its regulations anyway, setting the stage for rules that accomplish through regulatory revision what couldn't pass through legislation.

🤔 THINK ABOUT IT What's striking is the timing and scale: two major states are simultaneously moving to restrict or eliminate products that have never caused an overdose death, while alcohol—which kills approximately 95,000 Americans annually—remains freely available and heavily advertised. Veterans who've relied on legal THC products for PTSD and chronic pain now face limited alternatives in both Ohio and Texas, just as federal policy appears to be tightening nationwide. The hemp industry, which exploded into a multibillion-dollar market after the 2018 Farm Bill, is now experiencing a coordinated regulatory squeeze that threatens thousands of small businesses and eliminates consumer choice in states where these products were completely legal months ago.

March 21, 2026

A landmark review published in The Lancet Psychiatry has found no evidence that medicinal cannabis effectively treats anxiety, depression, or post-traumatic stress disorder — the three conditions patients most commonly cite when seeking medical marijuana. The analysis, led by Dr. Jack Wilson at the University of Sydney's Matilda Centre, examined over 50 randomized controlled trials conducted over 45 years, making it the largest systematic review of cannabis and mental health ever conducted. Researchers found that across nearly 2,500 patients studied in high-quality trials, cannabis performed no better than placebo for these disorders. For depression specifically, the review found not a single rigorous trial in the entire medical literature. "In the absence of evidence at this time, the routine use of medical cannabis products really should be rarely justified for the treatment of mental health disorders," Wilson told NPR.

The findings underscore a troubling gap between public perception and scientific reality. More than 700,000 Australians have used medicinal cannabis in the past year, with sales quadrupling since 2022, yet the majority of products prescribed in Australia remain unregistered with the Therapeutic Goods Administration and therefore untested. Anxiety, depression, PTSD, insomnia, and ADHD comprise six of the top ten reasons cannabis is prescribed globally. The review's authors note that while some mild to moderate side effects were common, serious safety concerns persist — particularly the risk of cannabis use disorder and psychotic symptoms, which could be worsened by routine cannabis use rather than improved. Dr. Wilson warned that medicinal cannabis may actually be "doing more harm than good by worsening mental health outcomes, and delaying the use of more effective treatments."

Where the evidence does show promise is narrower and more specific. The review found encouraging data suggesting cannabis may help reduce cannabis use disorder itself — similar to how methadone treats opioid dependence — and low-quality evidence for autism, insomnia, and tics or Tourette's syndrome. Cannabis has stronger evidence for treating seizures in certain forms of epilepsy, spasticity in multiple sclerosis, and specific types of pain, but mental health disorders remain unsupported by rigorous science. 🚀 THIS IS COOL The finding that cannabis medicines may help people quit cannabis by reducing cravings offers a genuine therapeutic avenue, even if the mechanism — an oral combination of CBD and THC — remains limited.

Even as the science shows limited evidence, policy is moving forward. 💰 MONEY MOVES The Centers for Medicare and Medicaid Services will launch a hemp products pilot program beginning April 1, 2026, allowing certain Medicare beneficiaries to receive up to $500 per year in federally legal hemp-derived products containing no more than 0.3% delta-9 THC through participating organizations. The program includes new safeguards: third-party testing for potency and contaminants, physician approval with documented shared decision-making, and exclusions for pregnant or breastfeeding beneficiaries and those with certain medical conditions. Medicare itself won't pay for the products, but the pilot signals a shift toward integrating cannabis into mainstream healthcare frameworks even as mental health applications remain unproven.

The collision between policy and evidence raises questions about regulatory standards. MarketWatch reported concerns that Medicare's plan could undermine FDA drug approval standards that have required decades to establish: if a product is intended to diagnose, treat, or mitigate disease, it must meet rigorous safety and efficacy testing. The pilot, by contrast, operates as an innovation program that bypasses traditional FDA pathways. While the new CMS guidance adds meaningful structure around testing, sourcing, and physician oversight, it proceeds amid a scientific consensus that the conditions most patients seek cannabis for — depression, anxiety, PTSD — lack evidence of benefit. 🤔 THINK ABOUT IT We're approving cannabis for mental health conditions that show no proof of efficacy, yet cannabis remains Schedule I federally, classified alongside heroin and with no accepted medical use. Meanwhile, alcohol kills approximately 95,000 Americans annually, opioids kill over 16,000 per year, and cannabis has never caused a recorded overdose death. The research gap is real and urgent, but so is the question of whether scheduling policy reflects actual public health risk or historical artifact.

March 21, 2026

Texas is about to ban most smokable cannabis products effective March 31, marking a dramatic shift in one of America's largest hemp markets. The Texas Department of State Health Services finalized new regulations on March 6 that will effectively prohibit THCA flower and smokable hemp by classifying THCA—a non-intoxicating compound that converts to delta-9 THC when heated—as part of the legal threshold calculation. Previously, Texas allowed hemp products containing up to 0.3% delta-9 THC. The new rules count THCA toward that limit, making most intoxicating smokable products illegal overnight. 💰 MONEY MOVES This creates an immediate financial crisis: retailers' annual licensing fees are jumping from $155 to $5,000, while manufacturer fees surge from $258 to $10,000—a 3,000% increase—giving businesses roughly four weeks to adapt or close.

The human cost is substantial and measurable. Hemp retailers estimate that smokable products represent 50-70% of their sales. Allen Kirk, managing partner at Full Spectrum in San Angelo, says THCA products account for 35-50% of his store's revenue; losing that segment while absorbing a $4,845 annual fee increase could force closure. Jacob Warner at Alamo Bud Co. in San Antonio reports that 70% of their sales are smokables. Mark Bordas, executive director of the Texas Hemp Business Council, estimates the rules will affect 8,000 registered hemp retailers and an industry generating $10-12 billion annually, potentially eliminating 50,000 jobs. The four-week implementation timeline means businesses cannot inventory-cycle their way through the transition—they must remove roughly half their product from shelves immediately or face penalties. Some San Antonio shop owners have already begun shutting down in anticipation.

🚀 THIS IS COOL The regulatory intent reflects a legitimate public health concern—ensuring products are accurately tested for psychoactive content—but the implementation raises a critical question about unintended consequences. Heather Fazio, director of the Texas Cannabis Policy Center, notes that veterans using smokable hemp for PTSD and chronic pain rely on the faster onset compared to edibles, which take 45 minutes to 90 minutes to take effect. When smokables disappear from legal markets, users historically shift toward unregulated street alternatives. Allen Kirk specifically warned that customers "are going to go back to the street. They're going to buy sketchy products from sketchy individuals." This mirrors decades of prohibition policy outcomes: banning legal cannabis doesn't eliminate demand; it pushes consumers into unregulated markets with zero testing, zero transparency, and genuine safety risks. Smokable products that went through state-tested retailers suddenly get replaced with products of unknown composition and origin.

The regulatory process itself moved at unusual speed. Governor Greg Abbott issued Executive Order GA-56 in September 2025, directing DSHS to revise hemp regulations. The agency proposed rules in January 2026, received feedback from over 1,400 commenters (most opposing the timeline and fee structure), then finalized the rules March 6 and set an effective date of March 31—a gap of just 25 days. Industry advocates called the timeline unrealistic for compliance. Some legal experts worry the compressed timeline will trigger enforcement confusion and potentially spike law enforcement raids on hemp businesses. Dallas attorney Chelsie Spencer has already documented cases where her clients—fully compliant retailers—were raided by local police and the DEA, with assets and inventory seized but no charges filed or convictions secured. Spencer's firm charges hemp retailers substantial fees just to maintain compliance with existing regulations; the new rules' complexity and speed will make that work even more expensive and uncertain.

🤔 THINK ABOUT IT Texas banned recreational marijuana in 1931 and has kept it banned for 95 years. The 2019 hemp loophole gave Texans a legal alternative that was tested, taxed, and traceable. Now those products are disappearing. Meanwhile, alcohol—which kills approximately 95,000 Americans annually—remains fully legal, widely available, and aggressively marketed. Cannabis has never caused a single recorded overdose death in human history. So which one needs emergency regulation to protect public health?